1-11 of 11
Martin Wermke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT174: A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies

Pau Abrisqueta, Reinhard Marks, Irit Avivi, Martin Wermke, Francesca Lim, Tae Min Kim, Alba Cabirta Touzon, Kristiina Karihtala, Shinichi Makita, Lillian Werner, Chiaki Tanaka, Anhthu Dang, Anwesha Chaudhury, Seth Rice, Rowshan Chowdhury, Deborah Knee, Belén Gomezcarrillo, Elissa Furutani, Koji Izutsu, Sirpa Leppä
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT174.
https://doi.org/10.1158/1538-7445.AM2024-CT174
Published: 05 April 2024
View article titled, Abstract CT174: A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies
Journal Articles

Abstract CT179: First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)

Johann de Bono, Stéphane Champiat, Francois-Xavier Danlos, Martin Wermke, Volker Kunzmann, Aude De Gassart, Emmanuel Valentin, Marina Iche, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Aurélien Marabelle, Daniel Olive, Paul Frohna
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT179.
https://doi.org/10.1158/1538-7445.AM2023-CT179
Published: 14 April 2023
View article titled, Abstract CT179: First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)
Journal Articles

Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma

Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, David Planchard, Dirk Schadendorf, Piotr Rutkowski, Jürgen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Tanay S. Samant, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Michele Moschetta, Adil Daud
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT197.
https://doi.org/10.1158/1538-7445.AM2022-CT197
Published: 15 June 2022
View article titled, Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with <em>NRAS</em>-mutant melanoma
Journal Articles

Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

Stephane Champiat, Martin Wermke, Johann de Bono, Aurelien Marabelle, Christiane Jungels, Cécile Vicier, Norbert Vey, Catrin List, Katrin Wetzko, Leo Ruhnke, Elena Garralda, Vladimir Galvão de Aguiar, Patricia LoRusso, Nuria Kotecki, Aude De Gassart, Emmanuel Valentin, Patrick Brune, Marina Iché, Céline Leparquier, Daniel Olive, Paul Frohna
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT188.
https://doi.org/10.1158/1538-7445.AM2022-CT188
Published: 15 June 2022
View article titled, Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial
Journal Articles

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Daniel S. Tan, Toshio Shimizu, Benjamin Solomon, Rebecca S. Heist, Martin Schuler, Maria J. De Miguel Luken, Anas Gazzah, Martin Wermke, Christophe Dooms, Herbert H. Loong, Neeltje Steeghs, Enriqueta Felip, Conor E. Steuer, Eric van Cutsem, Ross A. Soo, Ashley C. Jaeger, Jaeyeon Kim, Kun Xu, Xueying Chen, Xiaoming Cui, Heather Burks, Anna Farago, Philippe A. Cassier
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT033.
https://doi.org/10.1158/1538-7445.AM2022-CT033
Published: 15 June 2022
View article titled, Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors
Journal Articles

Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

Aurelien Marabelle, Christiane Jungels, Johann De Bono, Norbert Vey, Martin Wermke, Elena Garralda, Steven Le Gouill, Patricia LoRusso, Aude De Gassart, Emmanuel Valentin, Patrick Brune, Marina Iche, Daniel Olive, Paul A. Frohna
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT034.
https://doi.org/10.1158/1538-7445.AM2021-CT034
Published: 01 July 2021
View article titled, Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study
Journal Articles

Abstract 1506: Expansion kinetics and cytokine profiles of UniCAR-T-CD123, a rapidly switchable two-component CAR-T therapy, in patients with relapsed/refractory AML

Armin Ehninger, Julia Riewaldt, Cordula Gründer, Kristin Franke, Maria Schreiber, Martin Wermke, Sabrina Kraus, Carla Kreissig, Jan Koedam, Michael Pehl, Gerhard Ehninger, Marc Cartellieri
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1506.
https://doi.org/10.1158/1538-7445.AM2021-1506
Published: 01 July 2021
View article titled, Abstract 1506: Expansion kinetics and cytokine profiles of UniCAR-T-CD123, a rapidly switchable two-component CAR-T therapy, in patients with relapsed/refractory AML
Journal Articles

Abstract CT255: EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant NSCLC

Sebastian Michels, Lucia Nogova, Matthias Scheffler, Barbara Deschler-Baier, Martin Sebastian, Martin Schuler, Martin Wermke, Enriqueta Felip, Rafael Rosell, Delvys Rodriguez Abreu, Diana S.Y. Abdulla, Rieke N. Fischer, Sophia Koleczko, Anna Kron, Richard Riedel, Jan-Philipp Weber, Jana Fassunke, Sabine Merkelbach-Bruse, Heinz Haverkammp, Martin Hellmich, Reinhard Büttner, Jürgen Wolf, Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM)
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT255.
https://doi.org/10.1158/1538-7445.AM2020-CT255
Published: 15 August 2020
View article titled, Abstract CT255: EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant NSCLC
Journal Articles

Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

Bruce E. Johnson, Tae Min Kim, T. Jeroen N. Hiltermann, Fabrice Barlesi, Christian Grohe, Yasushi Goto, Orvar Gunnarsson, Tobias Overbeck, Noemi Reguart, Martin Wermke, Gilberto Castro Castro, Enriqueta Felip, Alastair Greystoke, Benjamin J. Solomon, Stephanie Deudon, Anne-Laure Louveau, Vanessa Passos, Daniel SW Tan
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT214.
https://doi.org/10.1158/1538-7445.AM2020-CT214
Published: 15 August 2020
View article titled, Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1<sup>st</sup> line therapy in patients (pts) with advanced or metastatic NSCLC
Journal Articles

JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter

Malte von Bonin, Katharina Moll, Michael Kramer, Uta Oelschlägel, Martin Wermke, Christoph Röllig, Christian Thiede, Gerhard Ehninger, Alwin Krämer, Carsten Müller-Tidow, Ioannis Mitroulis, Martin Bornhäuser
Journal: Cancer Research
Cancer Res (2018) 78 (21): 6339–6341.
https://doi.org/10.1158/0008-5472.CAN-18-0642
Published: 01 November 2018
View article titled, JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter
Open the PDF for JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter in another window
Journal Articles

Abstract LB-287: Identification of patients at risk for tumor predisposition syndromes based on the evaluation of sporadic cancer exome sequencing data: experiences from the NCT/DKTK MASTER program

Evelin Schrock, Barbara Hutter, Martina Fröhlich, Falk Zakrzewski, Sebastian Uhrig, Andreas Rump, Karl Hackmann, Joseph Porrmann, Laura Gieldon, Daniela Richter, Albrecht Stenzinger, Thomas Kindler, Wilko Weichert, Philipp J. Jost, Christian Brandts, Klaus Schulze-Osthoff, Johanna Falkenhorst, Sebastian Bauer, Frederick Klauschen, Konrad Klinghammer, Gunnar Folprecht, Martin Wermke, Karsten Spiekermann, Benedikt Brors, Stefan Gröschel, Christoph Heining, Peter Horak, Hanno Glimm, Stefan Fröhling, Barbara Klink
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): LB-287.
https://doi.org/10.1158/1538-7445.AM2017-LB-287
Published: 01 July 2017
View article titled, Abstract LB-287: Identification of patients at risk for tumor predisposition syndromes based on the evaluation of sporadic cancer exome sequencing data: experiences from the NCT/DKTK MASTER program